ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Hanyang, Seoul, KOR:

A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non...

Enrolling
B-cell Non Hodgkin Lymphoma
Drug: DR-0201

Phase 1

Dren Bio

Seoul, Korea, Republic of and 12 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Tafasitamab

Phase 1, Phase 2

Celgene
Celgene

Seoul, Korea, Republic of and 88 other locations

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This stu...

Active, not recruiting
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Drug: imvotamab

Phase 1, Phase 2

IGM Biosciences

Seoul, Korea, Republic of and 26 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

Seoul, Korea, Republic of and 188 other locations

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in...

Enrolling
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Drug: VAY736
Drug: lenalidomide

Phase 1

Novartis
Novartis

Seoul, Korea, Republic of and 19 other locations

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL....

Enrolling
B-cell Non Hodgkin Lymphoma
Drug: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)

Phase 1, Phase 2

AbClon

Seoul, Seoul, South Korea

JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leu...

Active, not recruiting
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Drug: JNJ-67856633
Drug: JNJ-64264681

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Seoul, Korea, Republic of and 27 other locations

is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...

Enrolling
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Dexamethasone
Drug: Ifosfamide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Seoul, Korea, Republic of and 48 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Prednisone
Drug: Lenalidomide

Phase 2

Genmab
Genmab

Seoul, Seoul Teugbyeolsi, Korea, Republic of and 74 other locations

study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non...

Active, not recruiting
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Drug: Capivasertib

Phase 2

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 16 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems